Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials-Reference-Cited by-同舟云学术

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials

Published:2017-04-03 Issue:7 Volume:19 Page:926-935
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Neal Bruce¹²³⁴^ORCID,Perkovic Vlado¹⁵,Mahaffey Kenneth W.⁶,Fulcher Greg⁵,Erondu Ngozi⁷,Desai Mehul⁷^ORCID,Shaw Wayne⁷,Law Gordon⁷,Walton Marc K.⁷,Rosenthal Norm⁷,de Zeeuw Dick⁸,Matthews David R.⁹,

Affiliation:

1. The George Institute for Global Health; Sydney Australia

2. The Charles Perkins Centre; University of Sydney; Sydney Australia

3. Royal Prince Alfred Hospital; Sydney Australia

4. Imperial College London; London UK

5. Royal North Shore Hospital and University of Sydney; Sydney Australia

6. Department of Medicine, Stanford Center for Clinical Research (SCCR); Stanford University; Stanford California

7. Janssen Research & Development, LLC; Raritan New Jersey

8. University Medical Center Groningen; University of Groningen; Groningen The Netherlands

9. University of Oxford; Oxford UK

Funder

Janssen Research & Development, LLC

Janssen Global Services, LLC

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12924/fullpdf

Reference18 articles.

1. Janssen Research & Development, LLC Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus 2013 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf

2. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study (CANVAS)-a randomized placebo-controlled trial;Neal;Am Heart J,2013

3. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial;Neal;Diabetes Obes Metab,2017

4. Janssen Research & Development Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE) ClinicalTrials.gov 2014 https://clinicaltrials.gov/ct2/show/NCT02065791

5. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis;Wu;Lancet Diabetes Endocrinol,2016

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory markers, oxidative stress, and mitochondrial dynamics: Repercussions on coronary artery disease in diabetes;World Journal of Diabetes;2024-09-15

2. Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney;Blood Pressure;2024-06-23

3. SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations;Frontiers in Nephrology;2024-04-15

4. Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials;Diabetes Care;2024-01-22

5. Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review);Russian Journal of Cardiology;2024-01-15